ADAPTIVEMOBILE-SECURITY
26.2.2018 07:02:08 CET | Business Wire | Press release
MOBILE WORLD CONGRESS – AdaptiveMobile Security, the world leader in mobile network security, today announced it has detected increasingly sophisticated attacks via the next generation of signalling protocols being used for 4G. In new research released at Mobile World Congress 2018, AdaptiveMobile presented the industry’s first ever overview of real-life attacks launched over the Diameter protocol.
“This research is the final piece of intel that will drive mobile operators to put defences in place to protect their networks against attacks over Diameter. Diameter vulnerabilities were theoretical up until now; however, this new research clearly demonstrates that they are actually being exploited in the real world, meaning the risk is real and must be addressed,” said Cathal Mc Daid, Chief Intelligence Officer of AdaptiveMobile Security.
To acquire these insights, the Company performed analysis of international Diameter traffic from ten operators’ networks worldwide and found suspicious activity within them. The research conducted analysed Diameter traffic travelling to and from more than 80 countries across five continents and detected a range of malicious activity, from simple to complex, over Diameter networks, affecting both mobile subscribers and mobile networks.
“Most importantly, carriers need to understand what is being detected and cannot rely on simple categorisation or rules to decipher what is malicious activity and what is not.” Mc Daid continued: “The threat is now proven, but without an added layer of intelligence, malicious traffic will be hidden in amongst the noise. This is critical, as Diameter use widens and SS7 security improves we expect rogue actors to exploit Diameter more and more.”
AdaptiveMobile has been working with operator networks around the globe to analyse their SS7 network data since launching its Signalling Protection in 2015. The Diameter protocol is the next-generation in signalling networks and as service providers roll out IP-based LTE networks – which present an evolved threat landscape – there is a growing demand for broader signalling protection on both SS7 and Diameter networks.
To learn more about AdaptiveMobile Security’s Signalling Protection product and industry-leading Threat Intelligence Unit, visit AdaptiveMobile at MWC in Hall 2, 2D100MR.
About
AdaptiveMobile Security
AdaptiveMobile Security
is the world leader in mobile network security, protecting over 1.7
billion subscribers worldwide, and the only mobile security company
offering products designed to protect all services on both fixed and
mobile networks through in-network and cloud solutions. With deep
expertise and a unique focus on network-to-handset security,
AdaptiveMobile’s award-winning security solutions provide its customers
with advanced threat detection and actionable intelligence, combined
with the most comprehensive security products on the market today.
AdaptiveMobile was founded in 2004 and boasts some of the world’s largest mobile operators as customers and the leading security and telecom equipment vendors as partners. The Company is headquartered in Dublin with offices in North America, Europe, South Africa, the Middle East and Asia Pacific.
https://www.adaptivemobile.com/
View source version on businesswire.com: http://www.businesswire.com/news/home/20180225005220/en/
Contact:
AxiCom for AdaptiveMobile Security
James Hayward, +44 7809 495 760
james.hayward@axicom.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
